AstraZenecaCEOPascal Soriot says that the vaccine results could be ready by the end of the year if trials resume. Clinical trials were temporarily suspended after a participant in the trials began to develop symptoms associated with transverse myelitis.
AstraZeneca CEO Pascal Soriot says that vaccine results could be ready by the end of the year if trails resume.
AstraZeneca CEO Pascal Soriot says that thevaccine results could be ready by the end of the year if trials resume.
AstraZeneca CEO Pascal Soriot says that the vaccine results could be ready by the end of the year if trials resume. Clinicaltrialsweretemporarilysuspendedafteraparticipantinthetrialsbegantodevelopsymptomsassociatedwithtransversemyelitis.